Lineage Cell stock holds steady as Roche presents positive 3-year data

Investing.com - Lineage Cell Therapeutics Inc. (NYSE:LCTX) maintained its position after H.C. Wainwright reiterated its Buy rating and $9.00 price target on the stock following positive clinical data presented by the company’s partner Roche/Genentech. According to InvestingPro data, analyst targets range from $1.50 to $9.00, with the stock showing remarkable momentum, gaining nearly 90% year-to-date.

On Saturday, Roche presented 3-year follow-up data from the Phase 1/2a study of Lineage’s cell therapy for geographic atrophy (GA) in patients with dry age-related macular degeneration (AMD (NASDAQ:AMD)) at the Clinical Trials at the Summit 2025 conference.

The data showed continued efficacy with just a single infusion of cells, which H.C. Wainwright noted provides "major and significant differentiation" compared to currently approved GA treatments that only slow disease progression.

This presentation marked the first clinical data update managed by Roche since partnering with Lineage, focusing on results from Cohort 4 of the Phase 1/2a study, including analyses of the overall patient group and separation by bleb coverage extent.

Roche is currently advancing the therapy in its Galette clinical study, with bleb coverage identified as a key focus area for the ongoing development program.

In other recent news, Lineage Cell Therapeutics, Inc. has announced a change in its auditing firm following a merger. Moss Adams LLP, the company’s previous auditor, merged with Baker Tilly US, LLP, leading to Moss Adams’ resignation. The Audit Committee of Lineage’s Board of Directors has approved Baker Tilly as the new auditor for the fiscal year ending December 31, 2025. Additionally, Lineage Cell Therapeutics reported a successful production run using a current Good Manufacturing Practice (cGMP) cell banking system. This system allows for the scalable and consistent production of cell-based product candidates from a single pluripotent cell line. The company notes the achievement but also cautions about the complexities and risks associated with maintaining this production capability on a commercial scale. These developments were disclosed in filings with the U.S. Securities and Exchange Commission, ensuring transparency with investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.